The board appointment adds an experienced biotech executive but does not change near-term outlook. Monitor the Phase 3 CoMpass trial (bel-sar for early choroidal melanoma) for topline data and regulatory updates, which are the primary catalysts.
Price Chart
Executive Summary
Aura Biosciences appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors as a Class II director, effective July 7, 2026, and amended its Non-Employee Director Compensation Policy to increase equity award sizes. This is a routine board appointment and compensation update with no immediate financial impact.
Key Facts
- Board size increased from 6 to 7; Jeremy Bender appointed to fill new vacancy
- Bender receives initial option for 60,000 shares and RSU for 30,000 shares, vesting over 3 years
- Non-employee director compensation policy amended June 11, 2026: initial options increased from 34,000 to 60,000; initial RSUs from 26,000 to 30,000; annual options from 17,000 to 30,000; annual RSUs from 13,000 to 15,000
- Bender previously CEO of Day One Biopharmaceuticals, which was acquired by Servier for ~$2.5 billion
- No financial statements or material financial data in this filing
Financial Impact
No direct financial impact; incremental equity compensation for directors is modest and routine
Risk Factors
- Clinical trial risks for bel-sar (Phase 3 CoMpass trial)
- Regulatory approval uncertainty for bel-sar in ocular oncology
- Dilution from increased director equity compensation is negligible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-297992 |
| Document: aura-ex10_1.htm | 0001193125-26-297992 |
| Document: aura-ex99_1.htm | 0001193125-26-297992 |
| Document: 0001193125-26-297992-index-headers.html | 0001193125-26-297992 |
| Document: 0001193125-26-297992-index.html | 0001193125-26-297992 |
| Document: 0001193125-26-297992.txt | 0001193125-26-297992 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $6.45 $6.56 | ▲ +1.71% | ▲ +2.27% | $6.26 (−2.95%) |
Aug 21, 2026 9w ago | EFFECT | $7.80 $6.36 | ▲ +18.46% | ▲ +17.94% | $6.26 (+19.74%) |
Aug 11, 2026 11w ago | 8-K | $8.04 $7.20 | ▲ +10.45% | ▲ +9.39% | $6.26 (+22.14%) |
Aug 11, 2026 11w ago | Press Release | $8.04 $7.20 | ▲ +10.45% | ▲ +9.39% | $6.26 (+22.14%) |
Jul 8, 2026 15w ago | 8-K | $7.25 $7.18 | ▼ −0.97% | ▼ −4.24% | $6.26 (−13.66%) |
May 19, 2026 22w ago | Press Release | $7.47 $6.34 | ▼ −15.13% | ▼ −15.87% | $6.26 (−16.20%) |
May 5, 2026 24w ago | 8-K | $8.29 $6.88 | ▲ +17.01% | ▲ +19.79% | $6.26 (+24.49%) |
May 5, 2026 24w ago | Press Release | $8.29 $6.88 | ▲ +17.01% | ▲ +19.79% | $6.26 (+24.49%) |
May 4, 2026 25w ago | 8-K | $8.90 $6.90 | ▼ −22.47% | ▼ −27.43% | $6.26 (−29.66%) |
May 4, 2026 25w ago | Press Release | $8.35 $7.19 | ▲ +13.89% | ▲ +19.54% | $6.26 (+25.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers